Biased neuromodulation lead and method of using same

Information

  • Patent Grant
  • 11883667
  • Patent Number
    11,883,667
  • Date Filed
    Thursday, April 21, 2022
    2 years ago
  • Date Issued
    Tuesday, January 30, 2024
    3 months ago
  • Inventors
  • Original Assignees
    • XII Medical, Inc. (Cleveland, OH, US)
  • Examiners
    • Malamud; Deborah L
    Agents
    • Fortem IP LLP
    • Hsu; Candice
    • Marcelo; Katrina
Abstract
A neuromodulation lead that is biased towards a substantially omega shape when fully deployed is provided. The neuromodulation lead includes a left set of electrodes disposed on a left portion of the lead body of the neuromodulation lead and a right set of electrodes disposed on a right portion of the lead body of the neuromodulation lead. The neuromodulation lead can be positioned in the plane between the genioglossus muscle and the geniohyoid muscle.
Description
TECHNICAL FIELD

The present disclosure relates to a neuromodulation lead and method for treating sleep disordered breathing.


BACKGROUND

Upper airway sleep disorders (UASDs) or sleep disordered breathing (SDB) are conditions that occur in the upper airway that diminish sleep time and sleep quality, resulting in patients exhibiting symptoms that include daytime sleepiness, tiredness and lack of concentration. Obstructive sleep apnea (OSA), the most common type of UASD, is characterized by cessation of airflow because of upper airway obstruction despite simultaneous respiratory effort. The respiratory effort continues despite obstruction until the individual is aroused from sleep. During sleeping the genioglossus muscle and other muscles that hold the airway patent relax, causing the mandible and the tongue to move posteriorly, which decreases upper airway volume. The obstruction causes a decrease in oxygen blood level, leading to increased respiratory drive and this cycle continues until the patient is aroused.


OSA is highly prevalent, affecting one in five adults in the United States. One in fifteen adults has moderate to severe OSA requiring treatment. OSA is the most common type of sleep apnea. Untreated OSA results in reduced quality of life measures and increased risk of disease including hypertension, stroke, heart disease, etc. Continuous positive airway pressure (CPAP) is a standard treatment for OSA. While CPAP is non-invasive and highly effective, it is not well tolerated by all patients and has several side effects. Patient compliance and/or tolerance for CPAP is often reported to be between 40% and 60%. Surgical treatment options for OSA, such as anterior tongue muscle repositioning, orthognathic bimaxillary advancement, uvula-palatal-pharyngoplasty, and tracheostomy are available too. However, they tend to be highly invasive (result in structural changes), irreversible, and have poor and/or inconsistent efficacy. Even the more effective surgical procedures are undesirable because they usually require multiple invasive and irreversible operations, they may alter a patient's appearance (e.g., maxillo-mandibular advancement), and/or they may be socially stigmatic (e.g., tracheostomy) and have extensive morbidity.


SUMMARY

Provided herein are neuromodulation leads and methods of treating SDB and other medical disorders. A neuromodulation lead can be used to stimulate the distal hypoglossal nerve trunk as well as distal branches of the hypoglossal nerve trunk that innervate the horizontal fibers and/or the oblique fibers within the genioglossus muscle as well as other muscles of the anterior lingual musculature. The application of stimulation to the hypoglossal nerve trunk and hypoglossal nerve distal fibers can enable airway maintenance during sleep for the treatment of SDB, such as obstructive sleep apnea (OSA). The neuromodulation lead can comprise a plurality of electrodes and can be configured or biased such that when positioned at the target site, such as between the geniohyoid and genioglossus muscles, the lead and the electrodes mirror the anatomy of the hypoglossal nerve bilaterally as the nerve approaches and starts to branch into the genioglossus muscle. In addition, or alternatively, the lead can be configured or biased to exert slight pressure on the genioglossus muscle and/or the hypoglossal nerve in an implanted configuration of the lead.


In an aspect, a neuromodulation lead is provided that comprises a lead body having a left portion, a right portion, and an intermediate portion therebetween. The lead body can be biased towards a substantially omega shape when fully deployed. The lead body can include a left set of electrodes disposed on the left portion of the lead body and a right set of electrodes disposed on the right portion of the lead body.


In another aspect, a neuromodulation lead is provided that comprises a lead body having a left portion, a right portion, and an intermediate portion therebetween. The lead body can be biased towards a substantially omega shape when fully deployed. The lead body can also include a left set of electrodes disposed on the left portion of the lead body and a right set of electrodes disposed on the right portion of the lead body. The location of the left and right set of electrodes on the respective left and right portion of the lead body can be based on the location of an electrical stimulation target site comprising the hypoglossal nerve trunk, distal branches of the hypoglossal nerve, nerve branches that innervate horizontal fibers within the genioglossus muscle, nerve branches that innervate oblique fibers within the genioglossus muscle, or suitable combinations thereof when the neuromodulation lead is fully deployed.


In another aspect, a neuromodulation lead is provided that comprises a lead body having a left portion, a right portion, and an intermediate portion therebetween. The lead body can include a left set of electrodes disposed on the left portion of the lead body and a right set of electrodes disposed on the right portion of the lead body. The intermediate portion can be biased towards an inferior position relative to the left and right electrode sets when the neuromodulation lead is fully deployed.


In another aspect, a method of treating SDB in a patient is provided. The method comprises obtaining a neuromodulation lead, positioning the neuromodulation lead between the geniohyoid muscle and the genioglossus muscle of the patient, and allowing the neuromodulation lead to assume a substantially omega shape within the plane between the geniohyoid muscle and the genioglossus muscle. The method can also include activating an electrode of the left set of electrodes, the right set of electrodes or both to apply an electrical signal to a target site to stimulate a nerve thereby treating the patient's SDB.


In another aspect, a method of treating SDB in a patient is provided. The method can comprise obtaining a neuromodulation lead comprising a lead body having a left portion, a right portion, and an intermediate portion therebetween. The lead can include a left set of electrodes disposed on the left portion of the lead body and a right set of electrodes disposed on the right portion of the lead body. The method can further include positioning the neuromodulation lead between the geniohyoid muscle and the genioglossus muscle of the patient and allowing the intermediate portion to assume an inferior position relative to the left and right electrode sets. The method can also include activating an electrode of the left set of electrodes, the right set of electrodes or both to apply an electrical signal to a target site to stimulate a nerve thereby treating the patient's SDB.





BRIEF DESCRIPTION OF DRAWINGS


FIG. 1 is a cut-away lateral view of the anterior lingual musculature, the hypoglossal nerve and exemplary terminal branches thereof, and surrounding bony structure, including the mandible, of a human.



FIG. 2 is a schematic transverse view of the geniohyoid muscle, the genioglossus muscle and the mylohyoid muscle of a human with the mylohyoid muscle oriented inferiorly and the genioglossus muscle oriented superiorly.



FIG. 3 is a schematic anterior depiction of an exemplary general arborization pattern and identification of the bilateral terminal branches of a hypoglossal nerve that innervate the genioglossus muscle (GG), the geniohyoid muscle (GH), and the hyoglossus muscle (HG) of a human. It should be noted that the hypoglossal nerve is illustrated as extending from the anterior mandible to the hyoid bone (i.e. from the top of the page to the bottom).



FIG. 4 is a top view of a neuromodulation device in a non-deployed configuration according to an aspect of the present disclosure.



FIG. 5 is a top view of a neuromodulation device in a fully deployed configuration according to an aspect of the present disclosure. The neuromodulation lead can be inserted either from the left side or the right side of the patient.



FIG. 6 is a schematic anterior view of a neuromodulation lead depicting the location of the electrodes on the lead body of the neuromodulation lead being adjacent to the location of distal branches of the hypoglossal nerve when the neuromodulation lead is fully deployed according to an aspect of the present disclosure. It should be noted that the hypoglossal nerve is illustrated as extending from the anterior mandible to the hyoid bone. (i.e. from the top of the page to the bottom)



FIG. 7 is a schematic anterior view of a neuromodulation lead depicting the location of the electrodes on the lead body of the neuromodulation lead being adjacent to the location of distal branches of the hypoglossal nerve when the neuromodulation lead is fully deployed according to another aspect of the present disclosure. It should be noted that the hypoglossal nerve is illustrated as extending from the anterior mandible to the hyoid bone. (i.e. from the top of the page to the bottom)



FIG. 8 is a perspective enlarged view of a neuromodulation device according to an aspect of the present disclosure.



FIG. 9 is a flow diagram of exemplary steps of a method of treating sleep disordered breathing according to an aspect of the present disclosure.



FIGS. 10-15 are schematic illustrations of different views of a neuromodulation device implanted in a patient identifying anterior lingual musculature, the hypoglossal nerve including branches thereof, and surrounding anatomical structures.



FIG. 16 is a transverse view of a neuromodulation device implanted in a patient identifying an illustrative incision and implantation site.





DETAILED DESCRIPTION

As used herein with respect to a described element, the terms “a,” “an,” and “the” include at least one or more of the described elements including combinations thereof unless otherwise indicated. Further, the terms “or” and “and” refer to “and/or” and combinations thereof unless otherwise indicated. By “substantially” is meant that the shape or configuration of the described element need not have the mathematically exact described shape or configuration of the described element but can have a shape or configuration that is recognizable by one skilled in the art as generally or approximately having the described shape or configuration of the described element. As used herein, “stimulate” or “modulate” in the context of neuromodulation includes stimulating or inhibiting neural activity. A “patient” as described herein includes a mammal, such as a human being. By “improving,” the patient's medical disorder is better after therapy than before therapy. As used herein, the terms, “inferior,” “superior,” “cranial,” and caudal refer to anatomical planes and directions when the patient is in a standard anatomical position. Similarly, the terms “left” and “right” refer to the position of elements that correspond to the left and right side of a patient's body in a standard anatomical position.


By way of background and with reference to FIG. 1, the hypoglossal nerve 10 controls many upper airway muscles that affect airway patency. The hypoglossal nerve 10 innervates the geniohyoid muscle 12, the intrinsic muscles of the tongue, and the extrinsic muscles of the tongue, such as the genioglossus muscle 14, the styloglossus muscle 16, and the hyoglossus muscle 18. The genioglossus muscle and the geniohyoid muscles 14 and 12 are primary muscles involved in the dilation of the pharynx. As schematically illustrated in FIG. 2, the geniohyoid muscle 12 is situated superior to the mylohyoid muscle 22 and inferior to the genioglossus muscle 14. Contraction of the genioglossus muscle 14 can provide tongue protrusion, hence widening of the pharyngeal opening. Activation of the geniohyoid muscle 12 along with a tone present in the sternohyoid muscle can pull the hyoid bone 20 ventrally, thus again dilating the pharynx. On the other hand, the hyoglossus muscle 18 and the styloglossus muscle 16 are considered tongue retractor muscles. As such, the hypoglossal nerve has several branches as it courses toward the anterior lingual muscles, and specifically to the genioglossus muscle. The branches innervate both retruser and protruser muscles of the anterior lingual system. It is believed that effective treatment of SDB requires stimulation of the protruser muscles without activation of the retruser muscles. Thus, for neuromodulation therapy to be effective it is considered important to localize stimulation to the protruser muscles while avoiding activation of the retruser muscles.


Referring back to FIG. 1 and as further schematically illustrated in FIG. 3, as the hypoglossal nerve 10 courses toward the anterior mandible, the first branches of the hypoglossal nerve 10 are branches that innervate the hyoglossus muscle (HG) and styloglossus muscles. The next branches of the hypoglossal nerve 10 are branches that innervate the geniohyoid (GH) and genioglossus (GG) muscles. In general, the number of branches varies individual to individual, but the course and direction of the branches are largely consistent individual to individual.


Although many methods of neuromodulating the anterior lingual muscles have been attempted, it is not known which branches are important to stimulate to achieve the desired efficacy for the treatment of SDB. It is believed that for treatment efficacy, a lead should be configured such that individual or small groups of individual branches can be activated as needed to achieve the desired effect.


A neuromodulation lead is provided herein that is configured to account for these and other considerations. In particular, a neuromodulation lead is provided that can be inserted and be positioned in the plane between the geniohyoid muscle and the genioglossus muscle. The neuromodulation lead can be configured to position electrodes along the nerve distribution of the hypoglossal nerve and its branches bilaterally. For example, and with reference to FIGS. 4 and 5, in an aspect, a neuromodulation lead 24 can comprise a lead body 26 having a left portion 28 comprising a left set of electrodes 34, a right portion 30 comprising a right set of electrodes 36, and an intermediate portion 32 therebetween. As described in more detail below, the electrodes can be used as stimulating electrodes to stimulate neural or neuromuscular tissue and/or as sensing electrodes to sense electrical activity, such as intrinsic or evoked electrical signals. Lead body 26 can be biased towards a substantially omega shape when fully deployed as shown in FIG. 5. In other words, lead body can be configured to transition from a substantially linear shape, as shown in FIG. 4, in a non-deployed state, such as during insertion, to a substantially omega shape, as shown in FIG. 5, when fully deployed. The neuromodulation lead is fully deployed when the neuromodulation lead is implanted in the patient's body and the electrodes are positioned at the desired locations in the patient's body. The omega shape of the neuromodulation lead can be created at the time of manufacturing such that the final form of the lead body is biased to have the omega shape, such bias being overcome if needed during insertion of the lead. The bias can be created, for example, by heat shaping or material shaping or other methods of manufacturing a biased lead. As stated above, the omega bias can allow the lead and the electrodes to mirror the anatomy of the hypoglossal nerve bilaterally as the nerve approaches and starts to branch into the genioglossus muscle.


A left set of electrodes 34 can be disposed on left portion 28 of lead body 26 and a right set of electrodes 36 can be disposed on right portion 30 of lead body 26. The electrodes can be used as stimulating electrodes. The electrodes can also be used as both stimulating and sensing electrodes for both stimulating target sites as well as sensing electrical activity, such as electromyogram activity, from the anterior lingual muscles. The electrodes can be ring electrodes extending substantially 360° about the lead body, for example, and can have substantially the same size as the target stimulation site(s). The electrodes can also be directional electrodes and not extend 360° about the lead body. Further, the electrodes can have electrode coatings to reduce the signal to noise ratio and/or allow for better long-term recording characteristics if used as sensing electrodes. If used as stimulating electrodes, an electrode coating can also allow the electrodes to have a larger charge injection profile for stimulation safety.


Intermediate portion 32 of lead body 26 can define an apex 38 and an ultrasound marker 40 can be disposed at apex 38. As such, the neuromodulation lead can be inserted via ultrasound and ultrasound marker 40 can allow the user to identify when the apex of the neuromodulation lead is positioned at midline, allowing the electrode sets 34 and 36 to be positioned along the distribution of the hypoglossal nerve and its branches bilaterally as illustrated in FIG. 6. Ultrasound can also be used to track motion or potential dislodgment of the lead over time. One or more anchors can be disposed on the lead body to secure the neuromodulation lead in place. Such anchors can be hard or soft anchors, for example, including tines, barbs, prefabricated sutures, deployable anchors including time dependent deployable anchors (e.g., anchors that are polymer coated and deploy or release once the polymer dissolves), or combinations thereof.


The lead body can have different shapes. For example, the lead body can be cylindrical, flat or have an oval cross-sectional shape. The lead body can also have enlarged segments to allow for disposition of larger electrode pads or contacts thereon along the length of the lead.



FIGS. 4 and 5 also illustrate an exemplary neuromodulation device 25 comprising neuromodulation lead 24 and including an exemplary power receiver 35 that can be operably coupled to neuromodulation lead 24. Power receiver 35 can include a coiled receiver antenna 37 configured to produce an induced current in response to being disposed in an electromagnetic field. The antenna can comprise a substrate having an upper surface and a lower surface, an upper coil comprising a plurality of coil turns disposed on the upper surface of the substrate, and a lower coil comprising a plurality of coil turns disposed on the lower surface of the substrate. The upper and lower coils can be electrically connected to each other in parallel. In particular, advantageously, antenna 37 can implement a unique two-layer, pancake style coil configuration in which the upper and lower coils are configured in parallel. As a result, the upper and lower coils can generate an equal or substantially equal induced voltage potential when subjected to an electromagnetic field. This can help to equalize the voltage of the coils during use, and has been shown to significantly reduce the parasitic capacitance of antenna 37. In this parallel coil configuration of antenna 37, upper and lower can be shorted together within each turn. This design has been found to retain the benefit of lower series resistance in a two-layer design while, at the same time, greatly reducing the parasitic capacitance and producing a high maximum power output. Such an antenna is described in more detail in co-pending U.S. patent application Ser. No. 16/865,541, entitled: “Implantable Stimulation Systems, Devices and Methods” filed on May 4, 2020 which is incorporated by reference herein specifically, paragraphs [0043], [0044], and FIGS. 9A and 9B. Neuromodulation device 25 can further comprise electronics package 39 with one or more electronic components 41 mounted therein configured to control the application of stimulation energy via one or more of the electrodes. The antenna can be configured to supply electrical current to the electronics package to power the electronics package. The antenna can be constructed from a flexible circuit board and the upper and lower coils can be etched from conductive layers laminated onto the substrate of the antenna. The electronics package can comprise one or more electronic components mounted on a portion of the flexible circuit board, wherein the flexible circuit board is configured to electrically connect the one or more electronic components to the antenna. The neuromodulation device can include pigtail connector 43, which can extend from electronics package 39 and can facilitate connecting lead 24 to the electronics package. Pigtail connector 43 can facilitate a detachable connection between electronics package 39 and lead 24 so that leads of different configurations can be connected to the electronics package. This can facilitate manufacturing of the neuromodulation device. This can also allow a physician to select a lead having a desired size and/or configuration.


Additionally, the neuromodulation lead being separate from, and connectable to, the remainder of the neuromodulation device via a pigtail connector, can facilitate implanting the lead separately. As a result, implanting the lead can be much less invasive, allowing the lead to be placed via a small incision. An integrated design may necessitate a larger incision and also the need to handle and manipulate the entire neuromodulation device as a whole during the implantation process, which could complicate the lead placement, as the surgeon could have to work around the remainder of the neuromodulation device, e.g., the electronics package and the antenna.


As depicted in FIG. 6, the location of left and right set of electrodes 34 and 36 on the respective left and right portion 28 and 30 of lead body 26 can be based on the respective left and right location of a stimulation target site comprising the hypoglossal nerve trunk 46, distal branches of the hypoglossal nerve such as terminal branches that innervate the genioglossus muscle indicated by reference characters GG1 to GG7 or both when neuromodulation lead is fully deployed. It should be noted that the number of branches depicted in FIG. 6 and other similar figures is only exemplary as the number of branches can vary from individual to individual as stated above. Rather, FIGS. 6-8 are provided to depict the general location of the branches of the hypoglossal nerve. The location of the left and right set of electrodes on the respective left and right portion of the lead body can also be based on the respective left and right location of stimulation sites comprising nerve branches that innervate horizontal fibers within the genioglossus muscle, oblique fibers within the genioglossus muscle, or both when the neuromodulation lead is fully deployed.


As depicted in FIGS. 5 and 6, left set of electrodes 34 and right set of electrodes 36 can be symmetrically disposed on lead body 26. Alternatively, as depicted in FIG. 7, a neurostimulation lead 24A can comprise a lead body 26A where the left set of electrodes 34A and the right set of electrodes 36A are asymmetrically disposed on the lead body to avoid the hyoglossus muscle branches, for example. For instance, in an aspect, the electrode configuration of the lead can be such that an electrode is not aligned with a hyoglossus muscle branch when the lead is implanted whereas an electrode is disposed on a distal more section 44 of right portion 30A of lead body 26A. Such an embodiment can avoid stimulating the hyoglossus muscle branch HG1, for example, since the hyoglossus muscle is a retruser muscle and given that the location of the hyoglossus muscle branch can be different on the left side of the hypoglossal nerve of a patient compared to the right side of the hypoglossal nerve as illustrated in FIG. 7.


In certain aspects and with respect to FIG. 8 and FIGS. 10-15, when neuromodulation lead 24B is fully deployed, intermediate portion 32B of lead body 26B defining apex 38B can be located inferior/caudal to the left and right electrode sets 34B and 36B respectively. This can be seen in the inferior bend or bias of lead body 26B that leads into intermediate portion 32B. Such a bend or bias can allow the lead to exert upward or cranial pressure to press the electrodes against the genioglossal muscle and/or the hypoglossal nerve to allow for better contact between the electrode sets and the hypoglossal nerve and/or genioglossus muscle. In particular, this pressure is created by the intermediate portion, including the apex, being more caudal in the body and allowing the left and right portion of the lead body to be pushed more cranially into the genioglossus muscle. This bias allows for better contact with the genioglossus muscle, more lead stability and hence better long-term performance of the lead.


In particular, such a bias can reduce motion of the lead after encapsulation/scar tissue grows around the lead and thus allow for better contact between stimulating electrodes and the target stimulation sites as well as better contact between sensing electrodes and the muscle(s) from which electrical activity is sensed. The inferior bias can also reduce the amount of encapsulating tissue around the lead as well. This can improve the recording of electromyography (EMG) signals from muscles innervated by the hypoglossal nerve since the more encapsulating tissue around the sensing electrodes, the harder it can be to detect an EMG signal long term. As such, reduced motion of the lead and less encapsulation of tissue around the lead can result in better EMG recording as well as stimulation of target sites at lower stimulation thresholds and more consistent responses from stimulation over time.


Neuromodulation lead 24B can also be part of a neuromodulation device 25B that includes a power receiver 35B and electronics package 39B. Power receiver 35B can include a coiled receiver antenna 37B (exemplary aspects of which are described above).


Referring to FIG. 9 and with reference to FIGS. 10-15, a method of improving SDB or another disorder is also provided using a neuromodulation lead. Such a method 100 can comprise obtaining a neuromodulation lead 24B (102) comprising left and right electrodes 34B and 36B respectively. FIGS. 10-15 also illustrates an exemplary neuromodulation device 25B with a power receiver 35B including a coiled receiver antenna 37B that is operably coupled to neuromodulation lead 24B. Method 100 can include inserting the neuromodulation lead in a patient's body (104) and allowing the neuromodulation lead to assume a substantially omega shape within the plane between the geniohyoid muscle GH and the genioglossus muscle GG (106). The hypoglossal nerve (HGN) and its branches (HGN′) are located in this plane bilaterally. Method 100 can further include aligning the right set of electrodes 36B and the left set of electrodes 34B with the nerve branches HGN′ of the hypoglossal nerve HGN (108). Method 100 can then comprise activating an electrode of the right set of electrodes 36B, the left set of electrodes 36B or both to apply an electrical signal to the hypoglossal nerve HGN to stimulate the hypoglossal nerve HGN thereby improving the patient's SDB (110). The method can also include avoiding stimulating hyoglossus muscle branches, the styloglossus muscle branches, or both. Although the method outlined above is described with respect to the neuromodulation device depicted in FIG. 8, it is understood that other embodiments of a neuromodulation device and neuromodulation lead can be used in such methodology.


Regarding an exemplary method of implanting a neuromodulation device, such a method can comprise inserting a stylet about the neuromodulation lead or into a lumen of the neuromodulation lead such that the neuromodulation lead assumes a substantially linear shape.


The method can further include percutaneously inserting the neuromodulation lead in a patient's body under ultrasound guidance, for example. The method can then comprise positioning the neuromodulation lead, for example, between the geniohyoid muscle and the genioglossus muscle plane of the patient. The method can further include retracting the stylet to allow the neuromodulation lead to assume a substantially omega shape, for example, within the plane between the geniohyoid muscle and the genioglossus muscle. The method can then include activating an electrode of the left set of electrodes, the right set of electrodes or both to apply an electrical signal to a target site to stimulate the hypoglossal nerve, for example, thereby treating a medical disorder such as the patient's SDB. The target site can be, for example, a hypoglossal nerve trunk, distal branches of the hypoglossal nerve, horizontal fibers within an anterior lingual muscle, oblique fibers within an anterior lingual muscle, or combinations thereof. The method can also include avoiding stimulating hyoglossus muscle branches, the styloglossus muscle branches, or both.


With respect to a specific exemplary percutaneous method of implantation, an insertion tool can be used to create a percutaneous puncture through the skin and subcutaneous tissue below the skin. When at the right depth, the insertion tool can create a curved path such that insertion of the neuromodulation lead does not penetrate into the genioglossus muscle but remains within the plane between the geniohyoid muscle and the genioglossus muscle. When positioned correctly, a small instrument can be deployed into the muscle plane and then swept anteriorly and posteriorly in line with the muscle plane to create a small space for the neuromodulation lead to be deployed between the geniohyoid muscle and the genioglossus muscle. Such steps can involve soft, blunt dissection of the muscle plane and not dissection of the muscle fibers. For example, a balloon dissection tool having a pre-configured balloon geometry can be inflated and cause separation between the muscles using gentle pressure. Once space is made for the neuromodulation lead, the small instrument can be retracted and the neuromodulation lead can be deployed. The lead can be deployed across midline, allowing the operator to visualize a midline ultrasound marker. Once positioned correctly, the neuromodulation lead can be deployed by removing the stiffener around or inside the lead, allowing the neuromodulation lead to take its natural omega shape, all within the plane between the geniohyoid and genioglossus. The insertion tool can be removed and the proximal end of the neuromodulation lead can be exposed through the skin.


With reference to FIGS. 10 and 16, another exemplary non-percutaneous method of implanting a neuromodulation device 25C uses a “pull along” lead approach instead of a stylet. Instead of using ultrasound and a percutaneous approach, such a surgical approach can utilize a small incision and dissection to allow visualization of the surgical plane in which the neuromodulation lead 24C is inserted. The procedure can start with approximately a 1.5 centimeter (cm) to 2 cm transverse incision 50 in the chin 52 fold (e.g., a sub-malar incision). This incision can be directed through the skin and subcutaneous fat and then, dissecting through the platysma muscle and sub-platysmal fat, the digastric muscles (left and right) can be located and the muscle raphe of the mylohyoid muscle (MH) can be identified. Using standard techniques, the mylohyoid raphe can be dissected and the surface of the geniohyoid muscle and its midline raphe can be identified. Again, using standard techniques, the raphe of the geniohyoid can be dissected through to expose a small portion (e.g., approximately 1 cm) of the plane between the geniohyoid muscle and the genioglossus muscle. This plane can be identified by the midline and lateral fat pads that surrounds the nerves and vascular that innervate the anterior lingual muscles (e.g., geniohyoid, genioglossus and others). These fat pads are where the hypoglossal nerve trunk and branches are localized.


Then a small curved needle can be inserted just medial to the jaw line and just anterior to the mandibular notch where the facial artery runs. The needle can be inserted with a medial and posterior approach, so that the tip of the needle enters into the plane exposed with the surgical dissection, e.g., the plane between the geniohyoid and genioglossus muscles. The needle can be inserted into the plane at the caudal border of the exposure and cross midline exiting the plane in a lateral direction. The needle can then exit the skin contralaterally to the original insertion location. The needle can be attached to the neuromodulation lead using a connector, such as a suture. The needle can be pulled through to allow the neuromodulation lead to enter the surgical plane. The connector can be removed and the position of the neuromodulation lead can be adjusted so that the electrodes align with the fat pads and the nerve branches of the hypoglossal nerve. The proximal end of neuromodulation lead can be exposed at the original insertion point and that proximal end can be connected to the electronic package and power receiver once the power receiver antenna coil is implanted. In particular, the power receiver antenna can be implanted in a caudal direction from the original transverse chin fold incision. The power receiver antenna can be implanted deep to the digastric muscles on top of the mylohyoid muscle (MH). Once the power receiver antenna is placed, the proximal end of the neuromodulation lead (via a connector, for example) can be tunneled to the power receiver antenna and connected. The muscle planes and the skin can be closed to complete the insertion.


Each of the disclosed aspects and embodiments of the present disclosure may be considered individually or in combination with other aspects, embodiments, and variations of the disclosure. Further, while certain features of embodiments and aspects of the present disclosure may be shown in only certain figures or otherwise described in the certain parts of the disclosure, such features can be incorporated into other embodiments and aspects shown in other figures or other parts of the disclosure. Along the same lines, certain features of embodiments and aspects of the present disclosure that are shown in certain figures or otherwise described in certain parts of the disclosure can be optional or deleted from such embodiments and aspects. Additionally, when describing a range, all points within that range are included in this disclosure. Further, unless otherwise specified, none of the steps of the methods of the present disclosure are confined to any particular order of performance. Furthermore, all references cited herein are incorporated by reference in their entirety.

Claims
  • 1. A method of treating sleep disordered breathing (SDB) in a patient, the method comprising: placing a distal portion of a neuromodulation lead between a geniohyoid muscle and a genioglossus muscle of the patient, wherein the distal portion of the neuromodulation lead comprises a left portion having a left set of electrodes, a right portion having a right set of electrodes, and an intermediate portion therebetween;aligning the left set of electrodes and the right set of electrodes with left nerve branches and right nerve branches of a hypoglossal nerve, respectively; andpositioning a proximal portion of the neuromodulation lead folded over itself such that the distal portion of the neuromodulation lead at least partially overlaps with an antenna that is coupled to the proximal portion of the neuromodulation lead.
  • 2. The method of claim 1, wherein placing the neuromodulation lead comprises placing the neuromodulation lead such that the intermediate portion of the lead is located caudal to the left and right portions of the neuromodulation lead.
  • 3. The method of claim 2, wherein placing the neuromodulation lead comprises placing the neuromodulation lead such that the left and right portions of the neuromodulation lead are pressed cranially into the genioglossus muscle via a bias in the neuromodulation lead.
  • 4. The method of claim 1, wherein aligning the left set of electrodes and the right set of electrodes comprises aligning the left portion of the neuromodulation lead and the right portion of the neuromodulation lead with the left nerve branches and the right nerve branches of the hypoglossal nerve, respectively.
  • 5. The method of claim 1, further comprising performing an incision in a chin fold of the patient and exposing a portion of a plane between the geniohyoid muscle and the genioglossus muscle.
  • 6. The method of claim 1, wherein at least one of the left set of electrodes and the right set of electrodes comprises at least one stimulating electrode.
  • 7. The method of claim 6, wherein the at least one stimulating electrode in the placed neuromodulation lead is configured to stimulate a target stimulation site comprising at least one of a hypoglossal nerve trunk, a distal branch of the hypoglossal nerve, a nerve branch that innervates horizontal fibers within the genioglossus muscle, and a nerve branch that innervates oblique fibers within the genioglossus muscle.
  • 8. The method of claim 1, wherein at least one electrode of the left set of electrodes and the right set of electrodes is usable as a sensing electrode.
  • 9. The method of claim 8, wherein the at least one sensing electrode is configured to sense electromyography (EMG) signals.
  • 10. The method of claim 1, wherein the neuromodulation lead comprises one or more anchors.
  • 11. The method of claim 10, wherein the one or more anchors comprises one or more tines, barbs, prefabricated sutures, deployable anchors, or a combination thereof.
  • 12. The method of claim 1, wherein the antenna is configured to produce an induced current in response to being disposed in an electromagnetic field.
  • 13. The method of claim 1, wherein the SDB is sleep apnea.
  • 14. The method of claim 1, further comprising positioning the antenna on a surface of a mylohyoid muscle of the patient.
  • 15. A method of treating sleep disordered breathing in a patient, the method comprising: placing a neuromodulation lead between a geniohyoid muscle and a genioglossus muscle of the patient, wherein the neuromodulation lead comprises a distal portion comprising a left portion having a left set of electrodes, a right portion having a right set of electrodes, and an intermediate portion therebetween;aligning the left set of electrodes and the right set of electrodes with left nerve branches and right nerve branches of a hypoglossal nerve, respectively;positioning the intermediate portion of the neuromodulation lead inferior to the left and right sets of electrodes, such that the intermediate portion pushes the left and right sets of electrodes further cranially into the genioglossus muscle; andpositioning a proximal portion of the neuromodulation lead folded over itself such that the distal portion of the neuromodulation lead at least partially overlaps with an antenna that is coupled to the proximal portion of the neuromodulation lead.
  • 16. The method of claim 15, wherein positioning the intermediate portion of the neuromodulation lead comprises positioning the intermediate portion outside of a plane along which the left and right sets of electrodes are oriented.
  • 17. The method of claim 16, wherein the neuromodulation lead comprises a preformed bend that biases the intermediate portion away from the plane.
  • 18. The method of claim 15, wherein aligning the left set of electrodes and the right set of electrodes comprises aligning the left portion of the neuromodulation lead with the left nerve branches of the hypoglossal nerve and aligning the right portion of the neuromodulation lead with the right nerve branches of the hypoglossal nerve.
  • 19. The method of claim 15, wherein at least one of the left set of electrodes and the right set of electrodes comprises at least one stimulating electrode.
  • 20. The method of claim 19, further comprising stimulating, with the at least one stimulating electrode, a target stimulation site comprising at least one of a hypoglossal nerve trunk, a distal branch of the hypoglossal nerve, a nerve branch that innervates horizontal fibers within the genioglossus muscle, and a nerve branch that innervates oblique fibers within the genioglossus muscle.
  • 21. The method of claim 20, further comprising avoiding stimulating a hyoglossus muscle branch, a styloglossus muscle branch, or both with the left and right sets of electrodes.
  • 22. The method of claim 15, wherein at least one electrode of the left set of electrodes and the right set of electrodes is usable as a sensing electrode.
  • 23. The method of claim 22, wherein the at least one sensing electrode is configured to sense electromyography (EMG) signals.
  • 24. The method of claim 23, further comprising sensing EMG signals from one or more muscles innervated by the hypoglossal nerve.
  • 25. The method of claim 15, wherein the neuromodulation lead comprises one or more anchors.
  • 26. The method of claim 25, wherein the one or more anchors comprises one or more tines, barbs, prefabricated sutures, deployable anchors, or a combination thereof.
  • 27. The method of claim 15, wherein the antenna is configured to produce an induced current in response to being disposed in an electromagnetic field.
  • 28. The method of claim 15, further comprising performing an incision in a chin fold of the patient and exposing a portion of a plane between the geniohyoid muscle and the genioglossus muscle.
  • 29. The method of claim 15, wherein the sleep disordered breathing comprises sleep apnea.
CROSS-REFERENCE TO RELATED APPLICATIONS

The present application is a divisional of U.S. application Ser. No. 16/865,668, filed on May 4, 2020, which claims priority to U.S. Provisional Application No. 62/915,194, filed on Oct. 15, 2019, each of which is incorporated by reference herein in its entirety.

US Referenced Citations (193)
Number Name Date Kind
4990160 Terino Feb 1991 A
5335657 Terry et al. Aug 1994 A
5522862 Testerman et al. Jun 1996 A
5591216 Testerman et al. Jan 1997 A
5609621 Bonner Mar 1997 A
5716377 Rise et al. Feb 1998 A
5877466 Bolongeat-Mobleu et al. Mar 1999 A
5988171 Sohn et al. Nov 1999 A
6240316 Richmond et al. May 2001 B1
6314324 Lattner et al. Nov 2001 B1
6587725 Durand et al. Jul 2003 B1
6770022 Mechlenburg et al. Aug 2004 B2
7660632 Kirby et al. Feb 2010 B2
7668591 Lee et al. Feb 2010 B2
7711438 Lettner et al. May 2010 B2
7885713 Campbell et al. Feb 2011 B2
8204602 Kallmyer Jun 2012 B2
8255056 Tehrani Aug 2012 B2
8498712 Bolea et al. Jul 2013 B2
8498713 Mashiach Nov 2013 B2
8574164 Mashiach Nov 2013 B2
8577465 Mashiach Nov 2013 B2
8577466 Mashiach Nov 2013 B2
8577467 Mashiach et al. Nov 2013 B2
8577468 Mashiach et al. Nov 2013 B2
8577472 Mashiach et al. Nov 2013 B2
8577478 Mashiach et al. Nov 2013 B2
8577647 Farritor et al. Nov 2013 B2
8585617 Mashiach et al. Nov 2013 B2
8588941 Mashiach Nov 2013 B2
8626304 Bolea et al. Jan 2014 B2
8644957 Mashiach Feb 2014 B2
8700183 Mashiach Apr 2014 B2
8718776 Mashiach et al. May 2014 B2
8744589 Bolea et al. Jun 2014 B2
8798773 Meadows et al. Jun 2014 B2
8812113 Mashiach Aug 2014 B2
8812135 Mashiach Aug 2014 B2
8831730 Mashiach et al. Sep 2014 B2
8838256 Mashiach et al. Sep 2014 B2
8897880 Mashiach Nov 2014 B2
8897895 Mashiach Nov 2014 B2
8903493 Mashiach et al. Dec 2014 B2
8903515 Mashiach Dec 2014 B2
8948871 Mashiach et al. Feb 2015 B2
8958893 Mashiach Feb 2015 B2
8989868 Mashiach et al. Mar 2015 B2
9031653 Mashiach May 2015 B2
9031654 Meadows et al. May 2015 B2
9044612 Mashiach et al. Jun 2015 B2
9061151 Mashiach et al. Jun 2015 B2
9061162 Mashiach et al. Jun 2015 B2
9095725 Mashiach Aug 2015 B2
9101774 Mashiach et al. Aug 2015 B2
9155899 Mashiach et al. Oct 2015 B2
9186511 Bolea Nov 2015 B2
9220907 Mashiach et al. Dec 2015 B2
9220908 Mashiach Dec 2015 B2
9248290 Mashiach Feb 2016 B2
9248302 Mashiach et al. Feb 2016 B2
9259585 Vajha et al. Feb 2016 B2
9302093 Mashiach Apr 2016 B2
9308370 Lima et al. Apr 2016 B2
9308381 Mashiach et al. Apr 2016 B2
9314613 Mashiach Apr 2016 B2
9314641 Meadows et al. Apr 2016 B2
9327132 Mashiach May 2016 B2
9339651 Meadows et al. May 2016 B2
9358392 Mashiach Jun 2016 B2
9370657 Tehrani et al. Jun 2016 B2
9393435 Mashiach Jul 2016 B2
9403009 Mashiach Aug 2016 B2
9403025 Mashiach et al. Aug 2016 B2
9409013 Mashiach et al. Aug 2016 B2
9415215 Mashiach Aug 2016 B2
9415216 Mashiach Aug 2016 B2
9421372 Mashiach et al. Aug 2016 B2
9463318 Mashiach et al. Oct 2016 B2
9486628 Christopherson et al. Nov 2016 B2
9757560 Papay Sep 2017 B2
9849288 Meadows et al. Dec 2017 B2
9950166 Mashiach et al. Apr 2018 B2
10029098 Papay Jul 2018 B2
10065038 Papay Sep 2018 B2
10105538 Bolea et al. Oct 2018 B2
10238468 Forsell Mar 2019 B2
10675467 Papay Jun 2020 B2
11291842 Caparso et al. Apr 2022 B2
11338142 Papay May 2022 B2
11351377 Papay et al. Jun 2022 B2
11351380 Caparso et al. Jun 2022 B2
11420061 Caparso et al. Aug 2022 B2
11420063 Caparso et al. Aug 2022 B2
11491333 Papay Nov 2022 B2
11691010 Caparso et al. Jul 2023 B2
11771899 Papay et al. Oct 2023 B2
20020010495 Freed et al. Jan 2002 A1
20040122787 Avinash et al. Jun 2004 A1
20060224211 Durand et al. Oct 2006 A1
20070160274 Mashiach Jul 2007 A1
20070239230 Giftakis et al. Oct 2007 A1
20070263915 Mashiach Nov 2007 A1
20080039904 Beutler et al. Feb 2008 A1
20080260229 Mashiach Oct 2008 A1
20090082831 Paul et al. Mar 2009 A1
20090226057 Mashiach et al. Sep 2009 A1
20090270960 Zhao et al. Oct 2009 A1
20100094379 Meadows et al. Apr 2010 A1
20100179562 Linker et al. Jul 2010 A1
20100241195 Meadows et al. Sep 2010 A1
20100260217 Redford Oct 2010 A1
20100280568 Bulkes et al. Nov 2010 A1
20100292769 Brounstein et al. Nov 2010 A1
20110071606 Kast et al. Mar 2011 A1
20110093032 Boggs et al. Apr 2011 A1
20110093036 Mashiach Apr 2011 A1
20110137376 Meskens Jun 2011 A1
20110230702 Honour Sep 2011 A1
20120010532 Bolea et al. Jan 2012 A1
20120010681 Bolea et al. Jan 2012 A1
20130085537 Mashiach Apr 2013 A1
20130085558 Mashiach Apr 2013 A1
20130204097 Rondoni et al. Aug 2013 A1
20130289401 Colbaugh et al. Oct 2013 A1
20140031840 Mashiach Jan 2014 A1
20140031902 Mashiach Jan 2014 A1
20140031903 Mashiach Jan 2014 A1
20140031904 Mashiach Jan 2014 A1
20140046221 Mashiach et al. Feb 2014 A1
20140052219 Mashiach et al. Feb 2014 A1
20140100642 Mashiach Apr 2014 A1
20140135868 Bashyam May 2014 A1
20140172061 Mashiach Jun 2014 A1
20140266933 Andersen et al. Sep 2014 A1
20140358026 Mashiach et al. Dec 2014 A1
20140358189 Mashiach et al. Dec 2014 A1
20140358196 Mashiach Dec 2014 A1
20140358197 Mashiach et al. Dec 2014 A1
20140371802 Mashiach et al. Dec 2014 A1
20140371817 Mashiach et al. Dec 2014 A1
20140379049 Mashiach et al. Dec 2014 A1
20150032177 Mashiach et al. Jan 2015 A1
20150073232 Ahmad et al. Mar 2015 A1
20150077308 Jeon et al. Mar 2015 A1
20150088025 Litvak et al. Mar 2015 A1
20150096167 Zhao et al. Apr 2015 A1
20150112402 Mashiach Apr 2015 A1
20150112416 Mashiach et al. Apr 2015 A1
20150142120 Papay May 2015 A1
20150224307 Bolea Aug 2015 A1
20150265221 Flanagan et al. Sep 2015 A1
20150283313 Huber Oct 2015 A1
20150290465 Mashiach Oct 2015 A1
20150343221 Mashiach Dec 2015 A1
20160094082 Ookawa et al. Mar 2016 A1
20160106976 Kucklick Apr 2016 A1
20160121121 Mashiach May 2016 A1
20160121122 Mashiach May 2016 A1
20160175587 Lima et al. Jun 2016 A1
20160184583 Meadows et al. Jun 2016 A1
20160235990 Mashiach Aug 2016 A1
20160346537 Mashiach Dec 2016 A1
20170087360 Scheiner Mar 2017 A1
20170128002 Christopherson et al. May 2017 A1
20170143257 Kent et al. May 2017 A1
20170143280 Kent et al. May 2017 A1
20170290699 Radmand Oct 2017 A1
20180015282 Waner et al. Jan 2018 A1
20180028824 Pivonka et al. Feb 2018 A1
20180117313 Schmidt et al. May 2018 A1
20180191069 Chen et al. Jul 2018 A1
20180280694 Mashiach Oct 2018 A1
20190117966 Kent Apr 2019 A1
20190151656 Bolea et al. May 2019 A1
20190160282 Dieken et al. May 2019 A1
20190247664 Yazoqui et al. Aug 2019 A1
20200016401 Papay et al. Jan 2020 A1
20200254249 Rondoni et al. Aug 2020 A1
20200269044 Papay Aug 2020 A1
20200346010 Papay et al. Nov 2020 A1
20200346016 Caparso et al. Nov 2020 A1
20200346017 Caparso et al. Nov 2020 A1
20200346024 Caparso et al. Nov 2020 A1
20210128914 Papay May 2021 A1
20220218988 Caparso et al. Jul 2022 A1
20220266030 Caparso et al. Aug 2022 A1
20220288390 Papay et al. Sep 2022 A1
20220323752 Papay Oct 2022 A1
20220370798 Caparso et al. Nov 2022 A1
20220401738 Caparso et al. Dec 2022 A1
20230024498 Caparso et al. Jan 2023 A1
20230277843 Caparso et al. Sep 2023 A1
20230310860 Papay Oct 2023 A1
Foreign Referenced Citations (85)
Number Date Country
2013208182 Oct 2013 JP
9219318 Nov 1992 WO
2005018737 Mar 2005 WO
2007080579 Jul 2007 WO
2007080580 Jul 2007 WO
2007080579 Jul 2007 WO
2007080580 Jul 2007 WO
2008129545 Oct 2008 WO
2009007896 Jan 2009 WO
2009007896 Jan 2009 WO
2009109971 Sep 2009 WO
2009109971 Sep 2009 WO
2009143560 Dec 2009 WO
2010006218 Jan 2010 WO
2011048590 Apr 2011 WO
2011077433 Jun 2011 WO
2013046032 Apr 2013 WO
2013046035 Apr 2013 WO
2013046038 Apr 2013 WO
2013046039 Apr 2013 WO
2013046040 Apr 2013 WO
2013046042 Apr 2013 WO
2013046043 Apr 2013 WO
2013046044 Apr 2013 WO
2013046048 Apr 2013 WO
2013046049 Apr 2013 WO
2013046053 Apr 2013 WO
2013057594 Apr 2013 WO
2013046032 Apr 2013 WO
2013046035 Apr 2013 WO
2013046038 Apr 2013 WO
2013046039 Apr 2013 WO
2013046040 Apr 2013 WO
2013046042 Apr 2013 WO
2013046043 Apr 2013 WO
2013046044 Apr 2013 WO
2013046048 Apr 2013 WO
2013046049 Apr 2013 WO
2013046053 Apr 2013 WO
2013057594 Apr 2013 WO
2013061164 May 2013 WO
2013061169 May 2013 WO
2013061164 May 2013 WO
2013061169 May 2013 WO
2013177621 Dec 2013 WO
2014016684 Jan 2014 WO
2014016686 Jan 2014 WO
2014016687 Jan 2014 WO
2014016688 Jan 2014 WO
2014016691 Jan 2014 WO
2014016692 Jan 2014 WO
2014016693 Jan 2014 WO
2014016694 Jan 2014 WO
2014016697 Jan 2014 WO
2014016700 Jan 2014 WO
2014016701 Jan 2014 WO
2014016684 Jan 2014 WO
2014016686 Jan 2014 WO
2014016687 Jan 2014 WO
2014016688 Jan 2014 WO
2014016691 Jan 2014 WO
2014016692 Jan 2014 WO
2014016693 Jan 2014 WO
2014016694 Jan 2014 WO
2014016697 Jan 2014 WO
2014016700 Jan 2014 WO
2014016701 Jan 2014 WO
2014047310 Mar 2014 WO
2014049448 Apr 2014 WO
2014057361 Apr 2014 WO
2014049448 Apr 2014 WO
2014057361 Apr 2014 WO
2014096969 Jun 2014 WO
2014096971 Jun 2014 WO
2014096973 Jun 2014 WO
2014096969 Jun 2014 WO
2014096973 Jun 2014 WO
2014207576 Dec 2014 WO
2014207576 Dec 2014 WO
2015004540 Jan 2015 WO
2015004540 Jan 2015 WO
2015139053 Sep 2015 WO
2017112960 Jun 2017 WO
2017173433 Oct 2017 WO
2022155632 Jul 2022 WO
Non-Patent Literature Citations (9)
Entry
Bailey, “Activities of human genioglossus motor units”, Respiratory Physiology & Neurobiology 179:14-22, 2011.
Björninen, Toni , et al., “The Effect of Fabrication Method on Passive UHF RFID Tag Performance”, International Journal of Antennas and Propagation, https://doi.org/10.1155/2009/920947, 2009, 8 pages.
Bjorninen, T. et al., “The effect of fabrication method on passive UHF RFID tag performance”, 2009, International Journal of Antennas and Propagation, vol. 2009, Article ID 920947, pp. 1-8.
Bailey, “Activities of human genioglossus motor units”, 2011, Respiratory Physiology & Neurobiology 179:14-22.
Cienfuegos et al., Mandible—Surgical approach—Intraocular—AO Surgery Reference, v1 .0 Dec. 1, 2008—(Accessed Apr. 18, 2016).
Cienfuegos et al., Mandible—Surgical approach—Submental—AO Surgery Reference, v1 .0 Dec. 1, 2008—(Accessed Apr. 18, 2016).
Schwartz, A.R. et al., “Electrical stimulation of the lingual musculature in obstructive sleep apnea”, 1996, Journal of Applied Physiology 81:643-652.
International Search Report and Written Opinion dated Apr. 22, 2022; International Application No. PCT/US2022/070101; 15 pages.
Katz, Eliot S., et al., “Genioglossus activity during sleep in normal control subjects and children with obstructive sleep apnea”, Am J Respir Crit Care Med. Sep. 1, 2004;170(5):553-60 (Year: 2004).
Related Publications (1)
Number Date Country
20220241588 A1 Aug 2022 US
Provisional Applications (1)
Number Date Country
62915194 Oct 2019 US
Divisions (1)
Number Date Country
Parent 16865668 May 2020 US
Child 17660042 US